Entrada Therapeutics, Inc.
News
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
Globe Newswire - Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration...\n more…
Entrada Therapeutics (NASDAQ:TRDA) Earns Outperform Rating from Oppenheimer
Ticker Report Oppenheimer reissued their outperform rating on shares of Entrada Therapeutics (NASDAQ:TRDA - Free Report) in a research report report published on Monday morning, Benzinga reports. The brokerage...\n more…
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Simply Wall St Celebrations may be in order for Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders, with the analysts delivering...\n more…
William Blair Analysts Decrease Earnings Estimates for Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Ticker Report Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Research analysts at William Blair decreased their Q3 2024 earnings per share (EPS) estimates for Entrada Therapeutics in a note issued to...\n more…
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Forecasted to Earn Q3 2024 Earnings of ($0.47) Per Share
Ticker Report Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2024 EPS estimates for Entrada Therapeutics in a research note issued to investors on...\n more…
Entrada Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.47) Per Share, HC Wainwright Forecasts (NASDAQ:TRDA)
Zolmax Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Research analysts at HC Wainwright dropped their Q3 2024 EPS estimates for shares of Entrada Therapeutics in a report issued on Wednesday...\n more…